Table 1 Baseline characteristics of participants in the general population and patients with CHB.

From: Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B

 

General population (n = 10,771)

CHB (n = 5680)

P

Age, years

46.9 ± 10.6

42.6 ± 11.2

< 0.001

Male patients, n (%)

5859 (54.40)

4073 (71.8)

< 0.001

BMI, kg/m2

23.87 ± 3.2

23.29 ± 3.1

0.923

Waist circumference, cm

81.76 ± 10.0

81.1 ± 13.5

0.004

Hip circumference, cm

94.73 ± 5.7

94.2 ± 24.9

0.045

ALT, U/L

21 (15–31)

34 (23–51)

< 0.001

AST, U/L

23 (19–28)

31 (25–42)

< 0.001

Fasting glucose, mmol/L

5.18 ± 1.2

5.96 ± 4.7

< 0.001

TG, mmol/L

1.65 ± 1.4

1.42 ± 2.9

< 0.001

Cholesterol, mmol/L

4.93 ± 0.9

4.36 ± 2.6

< 0.001

HDL-C, mmol/L

1.39 ± 0.4

1.43 ± 2.1

0.481

LDL-C, mmol/L

2.90 ± 0.8

2.52 ± 3.2

< 0.001

ALB, g/L

47.83 ± 2.6

46.35 ± 14.0

< 0.001

GLB, g/L

27.92 ± 3.8

30.57 ± 6.9

< 0.001

TB, μmol/L

14.21 ± 6.0

18.16 ± 12.7

< 0.001

DB, μmol/L

3.90 ± 1.7

6.12 ± 6.4

< 0.001

GGT, U/L

21 (13–38)

25 (16–44)

< 0.001

ALP, U/L

72 (60–87)

78 (63–97)

< 0.001

Platelet × 109/L

191 (152–232)

120 (80–164)

< 0.001

LSM, kPa

4.60 ± 1.2

10.02 ± 8.0

< 0.001

CAP, dB/m

241.99 ± 49.5

228.29 ± 49.8

< 0.001

  1. BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, TB total bilirubin, DB direct bilirubin, TG triacylglycerol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, GGT gamma glutamyltransferase, ALP alkaline phosphatase, LSM liver stiffness measurement, CAP controlled attenuation parameter.
Back to article page